HGH-CTP: Extension study data
Top-line data from 42 patients who were well titrated on a daily hGH therapy in a 4-month extension study of an open-label, dose-ranging, international Phase II trial showed that once-weekly injection of hGH-CTP led to average IGF-1 levels that were within the normal therapeutics range, +/- 2 standard deviations from the average IGF-1 levels expected in a normal population, in 88% of patients at 4 months vs. 86% of patients at the start of the study. Additionally, 81% of patients receiving hGH-CTP were within narrow normal range, +/- 1.5 standard deviations of normal IGF-1 levels, at 4 months vs. 69% at start of the study. Patients received once-weekly hGH-CTP at an initial dose containing 50% of the equivalent cumulative commercial dose that a patient would normally inject each day over the course of 7 days. On day 4, if a patient's IGF-1 level was below or above the narrow normal range the dose was increased or decreased by 33%, respectively. Data were presented at the joint International Congress of Endocrinology and European Congress of Endocrinology meeting in Florence. ...